Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

Top Cited Papers
Open Access
Abstract
No abstract available
Funding Information
  • Southwest Oncology Group ((SWOG)-8814, INT-0100)
  • National Cancer Institute, Department of Health and Human Services (CA38926, CA32102, CA21115, CA02599, CA60138, CA25224, CA77202-06, CA04920, CA58658, CA13612, CA37981, CA76447, CA22433, CA58416, CA20319, CA58686, CA04919, CA46441, CA58861, CA27057, CA32734, CA35281, CA12644, CA16385, CA45560, CA58882, CA14028, CA35176, CA46282, CA46113, CA52650, CA03096, CA28862, CA35090, CA58723, CA35283, CA45807, CA35200, CA35119, CA45450, CA46136, CA42777, CA35261, CA45466, CA35117, CA46368, CA58348, CA12213, CA52654, CA35128, CA58415, CA52623, CA35192, CA45377, CA35996, CA52757, CA76132, CA35431, CA76462, CA45461, CA35084, CA76429, CA35178, CA67663, CA63844, CA52772)

This publication has 31 references indexed in Scilit: